Insync_2000 Saturday, 05/23/20 10:56:57 AM Re: None Post # of 284509 This is something that has been rattling away in the back of my mind for a while now. Why wouldn't Amarin start a subsidiary to market generic vascepa through in the USA, should their effort to protect their brand name patent fail on appeal. Given that they are a one drug company that sells a relatively cheap drug, and that they already control supply, wouldn't it be a shoe in for them to be first in line should a pharmacist look for a generic version which in turn would make it less attractive for the generics to even enter the market. Seems to me that they are holding all the cards and don't seem to know what to do with them. They should be going after an ANDA right now through a subsidiary so that they are in position to protect their franchise should the appeal fail. Should they prevail in their appeal, collapse the subsidiary and move on with marketing the brand name product. What could it possibly cost. Probably well worth it for peace of mind and to protect their market Just a thought given that JT doesn't seem to have one.